knowledge -WSS

knowledge

author：leisure time 2025-09-06 07:17:31 - browse：365

President Joe Biden talks in the Roosevelt Room of the White House, in front of a painting of Theodore Roosevelt on a horse back — politics coverage from STAT — President Biden MANDEL NGAN/AFP via Getty Images

WASHINGTON — The White House is throwing its support behind a controversial authority that allows the government to undermine patent rights for certain high-priced medicines. It’s an early step that could have major ramifications for the American pharmaceutical industry, depending on whether and how federal officials actually use the authority.

The administration issued a framework for the National Institutes of Health to more broadly use so-called “march-in rights” — a policy that allows it to invalidate patent rights from drugmakers whose products rely on federally funded research. The framework lays out when the agency might assert this authority, and endorse using a drug’s price in that determination.

“We’ll make clear that when drug companies won’t sell taxpayer funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less,” White House National Economic Advisor Lael Brainard told reporters. “These authorities are in existing laws, the last administration just didn’t want to allow them to be used in this way.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Emergency medicine has repudiated 'excited delirium.' Now what?

WSS

Medtronic CEO on promising devices for diabetes, hypertension

Biden's order seeks to regulate AI risk without stifling innovation

Cybersecurity threat forces Lurie Children's to take systems offline

SAMSHA loosens regulations on methadone treatment centers

Physician subsidies by hospitals soar in wake of No Surprises Act

Commercial surrogacy can be ethical, despite pope’s claims

knowledge

knowledge

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Vertigo drug brings hope for rare neuron disorder, Niemann

Medicare details structure of new drug price negotiation program

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

George Santos makes 1st court appearance after pleading not guilty to 13 counts

General Catalyst, Summa Health deal will turn on physician buy

Trump demands the U.S. pay no more for drugs than other countries … again

New Ultima Genomics DNA sequencer can read genome for $100

Affirmative action in medical school literally saved lives

The pink breast cancer awareness ribbon needs a redesign

entertainment

Medicare drug price negotiation’s day in court

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

New Ultima Genomics DNA sequencer can read genome for $100

Traditional Chinese medicine benefits explored in new JAMA study

A $475,000 price tag for a new cancer drug: crazy or meh?

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

hotspot

explore

explore

leisure time